IQVIA HOLDINGS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IQVIA HOLDINGS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $9.74B | Feb 16, 2018 |
| FY2017 | Dec 31, 2016 | $6.88B | Feb 16, 2018 |
| FY2017 | Dec 31, 2015 | $5.74B | Feb 16, 2018 |
| FY2016 | Dec 31, 2014 | $5.46B | Feb 16, 2017 |
| FY2015 | Dec 31, 2013 | $5.10B | Feb 11, 2016 |
| FY2014 | Dec 31, 2012 | $4.87B | Feb 12, 2015 |
| FY2013 | Dec 31, 2011 | $4.33B | Feb 13, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.31B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $15.41B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $14.98B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $14.41B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $13.87B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $3.30B | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $2.79B | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $2.52B | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $2.75B | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $2.90B | Feb 12, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.37B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.36B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.09B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $966.00M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $119.00M | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $101.00M | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | ($23.00M) | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $82.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $16.00M | Feb 12, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.18B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.20B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $1.98B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $1.80B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.39B | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $289.00M | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $187.00M | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $62.00M | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $193.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $166.00M | Feb 12, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $3.34M | Feb 11, 2016 |
| FY2015 | Dec 31, 2014 | $5.79M | Feb 11, 2016 |
| FY2015 | Dec 31, 2013 | $4.96M | Feb 11, 2016 |
| FY2014 | Dec 31, 2012 | $10.43M | Feb 12, 2015 |
| FY2013 | Dec 31, 2011 | $9.99M | Feb 13, 2014 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.00B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.99B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $2.05B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $2.07B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.96B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.79B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.73B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $1.72B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $1.62B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.02B | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.65B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $2.72B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $2.15B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $2.26B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $2.94B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.96B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.42B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $1.25B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $970.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $860.00M | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.94B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $26.90B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $26.68B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $25.34B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $24.69B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $24.56B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $23.25B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $22.55B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $22.86B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $21.21B | Feb 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.31B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $20.83B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $20.57B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $19.57B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $18.65B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $18.28B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $16.99B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $15.60B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $14.61B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $12.35B | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.50B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $6.07B | Feb 17, 2026 |
| FY2021 | Dec 31, 2021 | $6.04B | Feb 16, 2022 |
| FY2021 | Dec 31, 2020 | $6.00B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $6.00B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $6.71B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $8.00B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $8.63B | Feb 16, 2018 |
| FY2016 | Dec 31, 2015 | ($564.00M) | Feb 16, 2017 |
| FY2015 | Dec 31, 2014 | ($704.06M) | Feb 11, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.62B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $14.71B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $14.57B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $13.92B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $13.30B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $12.65B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $12.16B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $11.80B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $11.85B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $10.73B | Feb 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.43B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $6.07B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $4.69B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.33B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.24B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.28B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $998.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $807.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $538.00M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | ($399.00M) | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.98B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.70B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $1.38B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.22B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.37B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.81B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $837.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $891.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $959.00M | Feb 19, 2019 |
| FY2018 | Dec 31, 2016 | $1.20B | Feb 19, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $10.27B | Feb 16, 2018 |
| FY2016 | Dec 31, 2016 | $7.22B | Feb 16, 2017 |
| FY2016 | Dec 31, 2015 | $2.50B | Feb 16, 2017 |
| FY2015 | Dec 31, 2014 | $2.31B | Feb 11, 2016 |
| FY2014 | Dec 31, 2013 | $2.06B | Feb 12, 2015 |
| FY2013 | Dec 31, 2012 | $2.44B | Feb 13, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 12, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 12, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 169.60M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 176.10M | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | 181.50M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 185.70M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 190.60M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | 191.20M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | 192.30M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | 197.50M | Feb 18, 2020 |
| FY2016 | Dec 31, 2016 | 248.30M | Feb 16, 2017 |
| FY2016 | Dec 31, 2015 | 119.40M | Feb 16, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2012 | $567.85M | Feb 12, 2015 |
| FY2013 | Dec 31, 2011 | $288.32M | Feb 13, 2014 |